Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VOYAGER THERAPEUTICS, INC.

(VYGR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/02/2021 12/03/2021 12/06/2021 12/07/2021 12/08/2021 Date
2.93(c) 2.65(c) 2.8(c) 3(c) 3.1 Last
426 154 509 210 499 686 415 138 218 676 Volume
+1.03% -9.56% +5.66% +7.14% +3.33% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 27,0 M - -
Net income 2021 -92,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,34x
Yield 2021 -
Sales 2022 22,2 M - -
Net income 2022 -110 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,36x
Yield 2022 -
Capitalization 118 M 118 M -
Capi. / Sales 2021 4,37x
Capi. / Sales 2022 5,31x
Nbr of Employees 178
Free-Float 86,0%
More Financials
Company
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company that is focused on developing treatments for patients suffering from severe neurological diseases. The Company's pipeline consists of programs for CNS indications, including HuntingtonÔÇÖs disease; a monogenic form of amyotrophic lateral sclerosis (ALS); and tau-related diseases including AlzheimerÔÇÖs disease, frontotemporal dementia (FTD) and... 
More about the company
Ratings of Voyager Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about VOYAGER THERAPEUTICS, INC.
11/29Verve Therapeutics Names Allison Dorval as Finance Chief
MT
11/19VOYAGER THERAPEUTICS : HER2+ Vectorized Antibody Presentation (SNO 2021)
PU
11/19VOYAGER THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
11/19Voyager Therapeutics, Inc. Announces CFO Changes Effective November 26, 2021
CI
11/19Voyager Therapeutics, Inc. Appoints Julie Burek as Principal Financial Officer and Prin..
CI
11/19Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 ..
AQ
11/19Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 ..
CI
11/16Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at th..
AQ
11/03Chardan Adjusts Price Target on Voyager Therapeutics to $4 From $5.50 While Awaiting In..
MT
11/02VOYAGER THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
11/02VOYAGER THERAPEUTICS : Q3 Earnings Snapshot
AQ
11/02Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results - Form ..
PU
11/02Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
AQ
11/02Voyager Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
10/20VOYAGER THERAPEUTICS : Says Preclinical Data Supports GBA1 Gene Therapy
MT
More news
News in other languages on VOYAGER THERAPEUTICS, INC.
11/29Verve Therapeutics nomme Allison Dorval au poste de directeur financier
10/20Voyager Therapeutics déclare que les données précliniques soutiennent la thérapie géniq..
10/11L'action de Voyager Therapeutics chute de 14%, le volume des transactions est trois foi..
10/06Le secteur de la santé reste à l'écart de la progression des marchés plus larges cet ap..
10/06Les actions de Voyager Therapeutics bondissent après l'accord d'option de licence avec ..
More news
Analyst Recommendations on VOYAGER THERAPEUTICS, INC.
More recommendations
Chart VOYAGER THERAPEUTICS, INC.
Duration : Period :
Voyager Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VOYAGER THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 3,10 $
Average target price 7,33 $
Spread / Average Target 137%
EPS Revisions
Managers and Directors
Michael J. Higgins Chairman, President & Chief Executive Officer
Glenn F. Pierce Chief Scientific Officer & Director
Mark Jay Levin Independent Director
James Arthur Geraghty Independent Director
Steven E. Hyman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VOYAGER THERAPEUTICS, INC.-58.04%114
MODERNA, INC.170.27%114 479
LONZA GROUP AG24.16%58 572
IQVIA HOLDINGS INC.50.86%51 638
SEAGEN INC.-16.39%26 777
CELLTRION, INC.-42.20%23 611